A quantum leap in our knowledge of breast cancer mutations by Caldas, Carlos & Edwards, Paul AW
Page 1 of 3
(page number not for citation purposes)
Available online http://breast-cancer-research.com/content/8/6/304
Last month our knowledge of genes mutated in breast cancer
took a quantum leap, with the publication in the journal
Science of the first results of a screen for mutations in the
coding sequences of 13,000 genes in human breast cancer
samples [1].
Although we believe that breast cancer is caused by
alterations to genes, we have very limited knowledge of what
genes get altered. It only takes a moment’s thought to realise
how big a limitation this is: with a catalogue of gene
alterations we could classify breast tumours, probably predict
their response to therapy, and design new targeted drugs.
We would also begin to understand the cell biology of breast
cancer – what distinguishes a benign from a malignant breast
tumour, which signalling pathways are disturbed, and so on.
The screen
Sjöblom and colleagues [1] determined the sequence of all
genes present on the consensus coding sequences database
(CCDS) in two common human cancers, breast and colorectal.
The work was divided into a discovery screen and a validation
screen. In the discovery screen the sequences of exons and
exon/intron boundaries of 14,661 transcripts corresponding
to 13,023 genes in CCDS were determined in 11 breast
cancer cell lines, 11 colorectal cancer xenografts and 2
normal samples. This represented a total of 456 megabases
of sequence data, corresponding to 91% of targeted bases in
CCDS. Sorting out this massive amount of data to discover
‘real’ somatic mutations and discard the remaining changes
(which, besides some ‘noise’, represent a treasure trove of
valuable data, for example of germline genetic variation) was
no simple task, both experimentally and computationally. In
total 816,986 putative nucleotide changes were found, which
then had to be filtered; 557,029 of these were non-
synonymous and were taken forward. The exclusion of false
positive calls and changes present in either of the two normal
controls or in single-nucleotide polymorphism databases
removed a further 96%. Resequencing removed 9,295 more.
The 19,986 ‘real’ nucleotide changes were sequenced in
matched normal DNA from the patients, showing that 18,414
were present in the germline as unknown polymorphisms and
leaving (after a further filtering step) a final tally of 1,307
confirmed somatic mutations in 1,149 genes. In the validation
screen, the 1,149 genes were sequenced in a further 24
breast and 24 colorectal cancers with matched normal DNA,
representing an additional 77 megabases of sequencing. With
the use of similar criteria to those of the discovery screen, of
133,693 putative changes only 365 somatic mutations were
confirmed in 236 genes. In summary, 9% (1,149) of the
13,023 genes sequenced in the discovery screen had
somatic mutations; among these, further mutations were
identified in 236 (21%) in the validation screen.
As in all such screens, a major issue is whether the mutations
observed are selected for in the cancer or are merely
accidental ‘passenger’ mutations. Different groups who have
screened for mutations have approached (or ignored) this
problem in different ways. The approach used by Sjöblom
and colleagues [1] was to estimate the mutation frequency
across the genome, allowing for gene size and different
frequencies of different base changes, and so estimate the
probability that a given gene is mutated more than the
expected frequency. The result is a set of genes estimated to
have more than 90% probability of undergoing selected
mutation, and called candidate cancer genes (‘CAN’ genes)
by the authors – 122 in the case of breast cancer.
Another way of working out whether mutations are
passengers is to compare the observed and expected
proportions of mutations that change protein sequence [2,3].
This strategy was not possible for the data set of Sjöblom
and colleagues because the non-synonymous sequence
changes found were not tested for in matching normal DNA.
Such data are available on a screen of kinases in breast
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cancer, where the estimate was that about one-third of
somatic mutations are selected [2]. This suggests that
Sjöblom and colleagues were conservative in their calcula-
tions (122 mutations in CAN genes out of 921 somatic
mutations), and that among the mutations in non-CAN genes
there were a significant number of selected mutations.
The meaning of what they found
The screen seems to tell us several profoundly important
things, of which we highlight the following:
1. A large number of mutated genes had not previously been
implicated in breast or other cancers. None of these were
mutated in a very high proportion of cases, but a number
are estimated to be mutated in around 10 to 20% of
(oestrogen receptor (ER)-negative) breast cancers.
2. A large number of mutations per tumour seem to be
selected for. Extrapolating to all of the coding sequences
in the human genome, the authors estimate an average of
20 CAN genes mutated per breast cancer. Although this
will not be a surprise to everyone, some textbooks have
got stuck with a much lower estimate of perhaps five to
seven. This number is often said to be supported by
age–incidence curves, but even Armitage and Doll [4],
who pioneered this kind of analysis, pointed out that the
five to seven estimate was valid only under rather
restrictive assumptions, for example that the rate of the
various events was constant over time.
3. There was a great deal of variation in the genes mutated
between cases.
4. There was almost no overlap between genes mutated in
breast and colon cancers, OBSCN (Obscurin) and
TP53/p53 being the only genes appearing in both lists of
CAN genes, although some other genes, such as AKAP6,
had mutations in both cancers but did not meet the
criteria for CAN genes.
5. Remarkably few of the mutations were scored as
homozygous. This may have reflected some technical
bias, but note that in the colorectal samples all except 3
out of 24 samples with APC mutations were scored as
homozygous or had two heterozygous mutations
(presumably bialleleic). This suggests that there are many
more dominant mutations than recessive (classic tumour
suppressor) mutations, and that mutation plus loss of
heterozygosity of tumour suppressor genes makes a very
small contribution to the development of breast and
colorectal cancer.
6. There was a very different mutation spectrum in colon and
breast, suggesting that the mutagenic processes in the
two tissues are different.
Putting findings in context
This marks a major step forward in the analysis of the gene
changes that drive breast cancer, because it made no
assumptions about what kinds of gene might be mutated.
This moves us forward dramatically from earlier targeted
screens.
What are its limitations?
Only 90% of about 13,000 genes have been examined so
far; the authors estimate that this is roughly two-thirds of the
whole human coding sequence (one obvious example of a
gene missed is PIK3CA) and does not include non-coding
regions and RNA transcripts including microRNAs.
The discovery screen examined only 11 breast cancer cell
lines: all were ER negative, so if there are genes that are
specifically mutated in ER-positive tumours – as seems
probable – these will have been missed in this screen. Given
the lack of overlap between breast and colon genes, this may
well be the biggest limitation of the screen.
The way in which the screen was analysed may well have
underestimated the number of ‘real’ mutations; that is, those
that are selected for or that are pathogenic. The authors note
that their discovery screen will have missed the rarer
mutations – only 50% of genes mutated in 6% of tumours
would have been found – and this is illustrated by the
absence of mutations in EP300, for example [5]. They used
the validation screen to provide evidence that a gene should
be on the significant list of 236 genes, but even a cursory
review of the genes found mutated in the discovery screen
suggests that more ‘real’ cancer genes are present in the list
of 1,149. For example, both AKAP6 and  AKAP9 had
mutations in both two breast and two colon cases, but did
not meet the CAN gene criteria. Baz1A and  Baz1B, two
proteins with a bromodomain adjacent to a zinc-finger
domain, were found mutated in the discovery screen,
suggesting that this gene family is a target of cancer
mutations. We also noted additional members of gene
families with a member included as a breast CAN gene were
found mutated in the discovery screen, for example CENTD3,
DNAH9,  ITGB2,  PRPF39,  LRRC4 and  LRRC7,  SEMA7A
and several solute carriers, suggesting that these genes
might also be ‘real’ breast cancer genes mutated at low
frequency.
Point mutation screens like this are also only part of what lies
ahead. As the authors point out, the point-mutation screens
cannot ‘see’ DNA rearrangements. Given the finding that 6%
breast cancers have translocations of the NRG1/heregulin
genes [6] and more than half of prostate cancers have
inversions, deletions or translocations that fuse members of
the  ETS transcription factors to an androgen-sensitive
transcript [7], this may be an important gap. And of course
the search for, and understanding of, epigenetic change is
only in its infancy.
What next?
We look forward to the screening of the remainder of the
transcriptome. Clearly, we also need ER-positive breast
cancer cases to be screened. We need more cases
screened to assess the frequency of the mutations picked up
so far, to improve the discrimination between passenger andPage 3 of 3
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cancer-relevant mutations. Then we need to know whether
these genes or others in the same pathways are targets for
other kinds of change – epigenetic changes, deletions,
amplifications, chromosome translocations and so on.
Further work is now necessary with the breast CAN genes
already identified: for example, in most cases it is not clear
what the mutations do to the genes’ function. The genes can
also be scanned for germline variation to determine their role
in cancer predisposition and in prognostication.
Perhaps the most exciting immediate prospect is a correlation
of mutation of these genes with molecular subtypes of breast
cancer that have been defined by expression analysis.
Conclusion
This screen represents a great leap forward in our knowledge
of breast cancer. It provides a long list of new cancer-relevant
genes and provocative information that forces us to re-
examine some of the assumptions we make about the
numbers and types of mutation in breast cancer. It vindicates
the large-scale unbiased screen as an approach to cancer.
However, it is only the first step towards an understanding of
the genome changes that drive breast tumorigenesis.
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